Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
Lisa Pleyer(Paracelsus Medical University), Richard Greil(Paracelsus Medical University), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Andre C. Schuh(University of Toronto), Konstantin Schlick(Paracelsus Medical University), Daniela Voskova(Women's General Hospital), C.L. Beach(Université Paris Cité), Angelika Pichler, Sabine Hojas, Alois Lang(Landeskrankenhaus Feldkirch), Armin Zebisch(Medical University of Graz), Michael Pfeilstöcker(Hanusch Hospital), Inga Mandac Rogulj(Klinička bolnica Merkur), Eva Maria Autzinger(Wilhelminen Hospital), Michael Girschikofsky(Krankenhaus der Elisabethinen), Wolfgang R. Sperr(Medical University of Vienna), Heinz Sill(Medical University of Graz), Klaus Geißler(University of Vienna), Reinhard Stauder(Innsbruck Medical University), John F. Seymour(The Royal Melbourne Hospital), Arlene S. Swern, Hartmut Döhner(University Hospital Ulm), Sigrid Machherndl Spandl(Krankenhaus der Elisabethinen), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Hervé Dombret(University of London Institute in Paris), Johannes Andel(Engineering Software Steyr (Austria)), Britta Halter(Innsbruck Medical University)
Cited by 51
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k